1554485-62-9

Upstream product

• 1255099-52-5 5-chloro-2-methylsulfanyl-pyrido[4,3-d]pyrimidine 
• 66975-53-9 2-1-ethoxy-meth-(Z)-ylidene-3-oxo-butyric acid ethyl ester 
• 7234-25-5 4-methyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 
• 1228565-00-1 4-((E)-2-dimethylamino-vinyl)-2-methylsulfanyl-pyrimidine-5-carboxvlic acidethyl ester 
• 902576-09-4 2-methylsulfanyl-6H-pyrido[4,3-d]pyrimidin-5-one 

Relevant academic research and scientific papers

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Compounds of the formula (I) in which R, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus